Bayer closing Richmond site
Bayer HealthCare said Thursday it plans to close its
research and biological development operations in
Richmond, company officials said. The company also
will close its research operation in West Haven,
Conn., by early 2008 as part of a larger worldwide
reorganization and consolidation, the company said
About 600 jobs, mostly research,
will be eliminated in the United States, with about 200
more job cuts in the future. Details were not available
about how many of those positions are based in Richmond
or West Haven. The moves are part of a plan to
consolidate the company's numerous research
organizations into three sites: Berlin and Weppertal in
Germany, and Berkeley.
Employees were notified of the
changes Thursday morning.
Bayer to close
Richmond facility, cut 300 jobs
Bayer HealthCare announced Thursday
that it will shutter its Berlex Biosciences facility in
Richmond, which Bayer acquired earlier this year as part
of its $21.5 billion purchase of
Schering AG of Germany.
At the same time Bayer has
selected Berkeley as one of three worldwide sites where
it will consolidate its R&D operations. The two others
will be in Berlin and Wuppertal in Germany.
The closure is expected to result
in the loss of some 300 jobs primarily in the R&D area
in The Bay Area. Bayer has facilities in Berkeley and
Richmond, with an estimated combined 1,900 employees.
The moves are part of a
realignment of Bayer Healthcare's global pharmaceutical
R&D organization, which also includes closing a site in
West Haven, Conn. The company will cut approximately 300
jobs there also.
According to company
spokespersons for Bayer and Berlex, most of the affected
positions in the Bay Area are likely to be at the
Richmond facility, although there may be positions
eliminated at Berkeley, as well.
Cathy Keck Anderson, a
spokeswoman for Berlex, declined to say how many people
work at the Richmond site, which has 10 buildings and
occupies approximately 355,000 square feet. However,
estimates are that there are about 400.
"This is a site closure so that
is why it is primarily research and development," said
Keck Anderson. "But clearly there are a number of
professions that work to support R&D and clearly they
may be impacted."
Berlex's Richmond site housed
programs for research in cancer and immuno-based
diseases, according to the company's Web site.